While semaglutide activates only the GLP-1 receptor, tirzepatide is a dual agonist that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
Author contributions JL and XL designed and outlined the work
This marks the first FDA-authorized treatment for NPC, a rare cancer
The Central Role of Enzymes as Biological Catalysts
Understanding room temperature stability matters for those who travel or have storage challenges
Despite this, people with type 2 diabetes tend to lose less weight on a GLP-1 than people who dont have the condition, and for reasons that arent quite clear, says Silvana Obici, MD, chief of the division of endocrinology at Stony Brook Medicine and medical director of the Stony Brook University Hospital Diabetes Center in New York